Tacrolimus- (FK 506) based immuno-suppression in severe systemic lupus erythematosus

Politt, Dirk; Heintz, Bernhard; Floege, Juergen; Mertens, PR

doi:10.5414/cnp62049

Cited by 30 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, a case series on the successful usage of TAC in eight SLE cases, including six patients with refractory nephritis and two with antiphospholipid syndrome, had been reported [20]. After that, several successful reports on TAC's eYcacy for nephritis [21][22][23][24][25][26][27], nephropathy after kidney transplantation for SLE [28,29], pediatric lupus nephritis [30], lupus cystitis [31], and neuromyelitis optica [32], were accumulated. Topical use of TAC, which had been approved for atopic dermatitis, had also begun to be tried for cutaneous lesions in lupus [33][34][35][36].…”

Section: Discussionmentioning

confidence: 99%

Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

et al. 2010

View full text Add to dashboard Cite

The aim of this study was to prospectively evaluate the efficacy and safety of tacrolimus (TAC) in various manifestations of systemic lupus erythematosus (SLE) patients in daily clinical practice. Each of the 21 TAC-treated patients with SLE in our care over 2 years was enrolled in this open-label trial. Patients were administered TAC at a dosage of 1-6 mg once daily, followed up for 24 weeks. Efficacy and safety were evaluated utilizing clinical and laboratory findings. As treatment targets, TAC was preferentially used with oral corticosteroid administration for mild active manifestations such as arthritis, skin eruptions, or asymptomatic nephritis. In efficacy, the mean value of the SLE disease activity index was significantly reduced to 4.1, 2.7, 1.8, and 1.2 (N=21, 20, 16 and 13) at 0, 4, 12, and 24 weeks, respectively. In eight cases, treatment was discontinued within 24 weeks due to insufficient effects (6 cases) and side effects (2 cases). Non-serious side effects were observed in only five cases (23.8%) over 24 weeks. TAC can be considered both effective and safe for the treatment of various manifestations of SLE.

show abstract

Section: Discussionmentioning

confidence: 99%

Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Tacrolimus is an immunosuppressant agent used to prevent or reverse rejection in organ transplant patients [1,2] and for refractory auto-immune disorders [4]. Tacrolimus is metabolized by hepatic CYP3A4 to inactive metabolites [5,6].…”

Section: Discussionmentioning

confidence: 99%

Acute tacrolimus toxicity in a non-transplant patient

O’Connor

Rusyniak

Mowry

2008

Clinical Toxicology

View full text Add to dashboard Cite

show abstract

“…[17] Subsequently, several reports have noted the efficacy of TAC for nephritis. [18][19] [20] Maintenance therapy of SLE has been reported only in studies of patients with lupus nephritis or without lupus nephritis, [21][22] [23] and in a small group study and a short-duration study. [24][25] Thus, there have been no previous assessments of long-term TAC therapy in a larger group of SLE patients with/without nephropathy, as performed in this study.…”

Section: Discussionmentioning

confidence: 99%

Steroid-sparing effect of tacrolimus in the maintenance phase of systemic lupus erythematosus: a single-center, prospective study

Otsuka¹,

Miwa²,

Ishii³

et al. 2014

cems

View full text Add to dashboard Cite

76Yusuke Miwa et al. AbstractObjective: The purpose of this study was to prospectively assess the steroid-sparing effect and safety of Tacrolimus (TAC) combination treatment during the maintenance phase of SLE.Methods: Thirty-eight patients were studied over a 1-year period from 2009 to 2012. If manifestations of mild active SLE, such as skin eruptions, arthritis, or asymptomatic nephritis, worsened and/or decreasing levels of serum complement (C3c) were observed, TAC combination treatment (from 1 mg to 5 mg once daily) was carried out. This was accomplished by adding TAC to the patient's existing treatment regimen and decreasing in the usage of prednisolone (PSL). Scores on the SLE Disease Activity Index (SLEDAI), PSL dosage, and proteinuria, serum levels of C3c, anti-dsDNA levels were researched.Results: Twenty-eight patients received to TAC combination therapy. 1) The PSL dose was decreased from 11.7 ± 5.6 to 8.2 ± 4.2 mg/day (P<0.001).2) The serum concentration of C3c increased and levels of anti-dsDNA antibodies decreased 3) Scores on the SLEDAI modified from 6.2 ± 3.7 to 2.6 ± 2.3 (P<0.001). There were no significant differences in proteinuria. In contrast, eight patients did not respond and/or had worsening SLE, and two patients discontinued treatment because of an adverse effect such as rhabdomyolysis or muscle cramps. No patients had complications of an abnormal urinalysis, and none progressed to renal failure with or without requiring dialysis.Conclusions: TAC combination treatment may have a useful steroid-sparing effect, as it does not worsen disease activity and is safe for SLE patients during the maintenance phase.

show abstract

Tacrolimus- (FK 506) based immuno-suppression in severe systemic lupus erythematosus

Cited by 30 publications

References 0 publications

Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

Acute tacrolimus toxicity in a non-transplant patient

Steroid-sparing effect of tacrolimus in the maintenance phase of systemic lupus erythematosus: a single-center, prospective study

Contact Info

Product

Resources

About